Rapid Influenza Diagnostic Tests (RIDT) Market Size & Share 2026-2035

Rapid Influenza Diagnostic Tests Market Size

The global rapid influenza diagnostic tests market was estimated at USD 1.5 billion in 2025. The market is expected to grow from USD 1.6 billion in 2026 to USD 2.5 billion in 2035, at a CAGR of 4.9% during the forecast period, according to the latest report published by Global Market Insights Inc.

The market is driven by numerous factors such as increasing popularity of rapid diagnostic tests, technological advancements, rising demand for early influenza diagnosis and management, among other factors.

Advancements in immunoassay and lateral‑flow technologies, increasing demand for point‑of‑care diagnostics, and emerging markets in Asia-Pacific are expected to fuel the industry's growth. Abbott, Becton, Dickinson and Company (BD), Quidel Corporation, Roche, and Thermo Fisher Scientific, are among the leading players operating in the market. These players mainly focus on product innovation, geographic expansion, integration of advanced technologies, strong R&D, and collaboration with local or regional healthcare providers, among others.
 

The market has increased from USD 1.1 billion in 2022 and reached USD 1.4 billion in 2024, with the historic growth rate of 10%. The market for rapid influenza diagnostic tests (RIDTs) is projected to grow tremendously due to the rising seasonal flu cases, increased adoption of point-of-care testing, and innovation in diagnostic methods. In addition, government initiatives aimed at improving the surveillance of influenza and conducting awareness campaigns are contributing significantly to broadening the market.
 

Additionally, the accuracy of tests has significantly improved due to new digital rapid tests for influenza diagnostics with better sensitivity and specificity, making these tests essential for healthcare providers. The shift from qualitative to semi-quantitative RIDTs has also been beneficial for diagnostics. The introduction of multiplexed tests, which can detect influenza along with other respiratory pathogens, has increased the clinical utility of RIDTs. Artificial intelligence (AI) and machine learning technologies support these advancements by automating test interpretation and reducing errors. With more spending on healthcare infrastructure, these technologies are making RIDTs more widely available to a greater number of patients.
 

Governments in various countries are increasing their efforts to improve the supervision and diagnosis of influenza to reduce the burden caused by the disease. The U.S. CDC's Influenza Division International Program, and The World Health Organization's Global Influenza Surveillance and Response System, have highlighted the importance of accurate diagnosis in the early stages of the disease. Agencies like the FDA and the EMA are supporting seasonal diagnosis by fast-tracking the approval of RIDTs.
 

Moreover, a growing number of public health systems are receiving grants and subsidies for diagnostic testing, which drives further market growth. These grants help improve public health systems and increase patient awareness about the importance of timely treatment and diagnosis through a multi-channel marketing approaches. These regulations also foster early treatment and diagnosis through marketing campaigns that enhance public awareness about such issues.
 

Rapid influenza diagnostic tests (RIDTs) are immunoassays that identify the presence of influenza A and B viral nucleoprotein antigens in respiratory specimens and display the results in a qualitative manner. RIDTs can provide results in less than 15 minutes.

Rapid Influenza Diagnostic Tests Market Trends

Novel technologies, the integration of AI tools, changing consumer demands, and a transformation in the delivery of healthcare services are some of the key trends supporting the growth of the RIDT market.
 

• AI-powered RIDTs improve accuracy, minimize false positives and negatives, and enhance the efficiency of the diagnostic process in both clinical and point-of-care settings. Significant progress has been made in this area to ensure that individuals are accurately diagnosed and treated in a timely manner.
   
• In addition, market growth is also expected to increase during the forecast period due to the rising popularity of home-testing kits. With the surge in telehealth services combined with the ease of self-testing, patients are able to self-test for influenza, get immediate results, and consult with healthcare professionals through video calls. This change is significantly more noticeable since the COVID-19 pandemic, as there is a greater emphasis on accessing healthcare services in a quick and efficient manner.
   
• Further, the evolution of markets is being driven by the increased availability of multiplex diagnostic tools. With these methods, patients can detect influenza A and B simultaneously with other viral respiratory infections like RSV and SARS-CoV-2. This helps provide a greater overall diagnostic solution while eliminating the need to take multiple tests.
   

Rapid Influenza Diagnostic Tests Market Analysis

Based on product type, the market is segmented as conventional RIDTs and digital RIDTs. The conventional RIDTs segment generated revenue of USD 898.8 million in 2025. Faster turnaround time compared to molecular tests is anticipated to fuel the segmental growth. The segment is expected to reach USD 1.4 billion by 2035, growing at a CAGR of 4.6% during the forecast period.
 

• Conventional RIDTs are popular in the market because they are affordable and easy to find. These tests are simple to produce and do not need much infrastructure, making them suitable for areas with limited resources. Their low cost is especially helpful in public health campaigns in developing countries, where tight budgets often restrict access to healthcare.
   
• Additionally, conventional RIDTs are easy to use and don’t require specialized training, which makes them ideal for places like clinics, schools, and workplaces. Their fast results help healthcare providers make quick decisions, which is especially important during busy flu seasons. This simplicity has made them a key tool in managing seasonal flu outbreaks.
   
• The digital RIDTs segment is expected to grow at a CAGR of 5.4% during the forecast period. Analyzer-based readers for digital rapid influenza diagnostic tests interpret the antigen test results with much more consistency than with human review.
   
• Further, they improve sensitivity relative to traditional tests that depend on human interpretation using optical, fluorescence, or algorithm-based signal detection methods.
   
• Many digital rapid influenza diagnostic test (RIDT) kits also have the ability to connect to a data repository automatically manner for entering, reporting, and linking data with clinical information systems, making them easier to use, quicker to read, and more suited for decentralized clinical use.
   

Based on technology, the rapid influenza diagnostic tests market is segmented into immunochromatographic assays, lateral flow assays, polymerase chain reaction, and other technologies. The immunochromatographic assays segment accounted for a leading share of 51.4% in 2025.
 

• Immunochromatographic assays held a substantial market share in 2025, due to their excellent sensitivity and specificity. These tests can identify even small amounts of the virus, ensuring accurate results. This is especially important for detecting infections early in high-risk groups like children and the elderly, helping to prevent serious complications.
   
• These assays are also becoming more common in decentralized testing locations, such as pharmacies and urgent care centers. Their small size and minimal equipment requirements make them a practical option for these settings. Additionally, advancements in technology have made these tests faster and more reliable, and hence healthcare providers increasingly prefer them.
   
• The lateral flow assays segment held a significant share with a revenue of USD 331.5 million in 2025. Due to their ease of use, quicker results, and minimal workload associated with them, lateral flow assays are among the most popular technologies for rapid detection of influenza virus.
   
• In addition, the process of immunochromatography is used by the assays. In this technique, the influenza antigens interact with labeled antibodies as they move along the testing device (the test strip), with the result being presented as visible lines (positive or negative) in a few minutes.
   
• Further, the limited equipment required to conduct lateral flow using RIDTs makes them suitable for use in clinics, emergency departments, and community health programs.
   

Based on sample type, the rapid influenza diagnostic tests market is segmented into nasal swab, throat swab, and other samples. The nasal swab segment is expected to drive business growth and expand at a CAGR of 5.7%, reaching around USD 1.3 billion by 2035.
 

• The segment is controlled by the nasal swab region as it is simple to use and provides accurate results. Swabs cause low tissue irritation, making them suitable for both children and adults. It is commonly used in clinics for influenza cases, which also helps grow the market.
   
• Additionally, nasal swabs are multi-functional as they fit regular and molecular RIDTs. They are optimal for early diagnosis of influenza because they capture high viral loads. Providers equally benefit from nasal swabs because of their reliable performance in point-of-care and laboratory test systems.
   
• The throat swab segment is witnessing significant growth with a revenue of USD 578.7 million in 2025. Throat swabs are a common way to detect Influenza virus, particularly in patients who are unable to have a nasal swab or when nasal swabbing is not possible.
   
• Further, the throat swab is done by using a stick to swab the back of the throat and collect any virus or liquid from the throat. The sample is then tested using one of three testing platforms: antigen, molecular, or digital RIDT.
   
• Although throat swabs generally provide somewhat lower viral loads than nasopharyngeal swabs, they are widely used because they are easy to obtain, provide comfort to the patient and are appropriate for multiple types of clinics.
   
• Furthermore, the proper method for collecting the sample is critical to the accuracy of the test result and will help ensure that health professionals can screen for influenza accurately in any type of outpatient clinic, hospital, or community care facility.
   

 

Based on end use, the rapid influenza diagnostic tests market is segmented as diagnostic centers, hospitals, research laboratories, and other end users. The diagnostics centers segment dominated the market with a revenue share of 41.4% in 2025.
 

• Diagnostic centers are the top end-users in the RIDT market because they have advanced facilities and skilled staff. These centers use state-of-the-art technology to deliver accurate and efficient testing. Patients often choose diagnostic centers for reliable results, especially for molecular RIDTs that require specialized equipment.
   
• Additionally, there is also a growing demand for comprehensive testing, including multiplex diagnostics, which has increased the use of RIDTs in diagnostic centers. These centers offer a variety of testing options, helping healthcare providers distinguish between influenza and other respiratory illnesses. Their involvement in large-scale influenza monitoring programs further strengthens their leading role in the market.
   
• The hospitals segment was valued at USD 391.4 million in 2025. Due to a large number of patients, critical management of patients with severe illness, and the need for timely, evidence‑based treatment decisions, hospitals are a significant end use market for influenza test diagnostic products.
   
• Hospitals use RIDT for rapid triage, isolation, initiation of antiviral treatment, and outbreak management. Emergency departments use rapid antigen or digital assay tests, while inpatient and laboratory settings tend to use high‑accuracy testing methods such as PCR.
   
• Further, hospitals benefit from the availability of integrated workflows, connectivity through digital channels, and multi‑pathogen platforms that can differentiate influenza from other respiratory diseases.
   

 North America Rapid Influenza Diagnostic Tests Market
 

North America rapid influenza diagnostic tests industry accounted for majority share of 34.4% in 2025 and is anticipated to show notable growth over the forecast period.
 

• The U.S. market was valued at USD 365.8 million and USD 401.3 million in 2022 and 2023, respectively. In 2025 the market size was valued at USD 479.3 million from USD 439.3 million in 2024.
   
• The U.S. dominates North America's RIDT market due to strong healthcare policies, high disease awareness, and significant investment in diagnostic tools. Programs like Vaccines for Children (VFC) help provide flu diagnostics and vaccinations to underserved populations. The increased use of RIDTs at retail pharmacies such as CVS and Walgreens, along with telehealth services, has made influenza testing more accessible for many people.
   
• In addition, government programs like the National Influenza Pandemic Strategy have also supported these RIDT initiatives. To satisfy the growing demand, large companies like Roche Diagnostics and Quidel have moved their operations to the U.S. Additionally, there is a growing trend of integrating RIDTs into corporate wellness programs, encouraging their use in office environments.
   

Europe Rapid Influenza Diagnostic Tests Market
 

Europe accounted for a significant share of the global rapid influenza diagnostic tests  industry and was valued at USD 414.7 million in 2025.
 

• There is a notable growth in RIDT usage in Europe because of a focus by healthcare systems on quicker detection of respiratory infections and improved preparation for seasonal trends in flu.
   
• In addition, countries across Western and Northern Europe are integrating rapid testing into primary care networks, elderly care facilities, and emergency departments to reduce diagnostic bottlenecks. Governmental regulations create incentives for the use of high-quality digital and molecular rapid tests.
   
• Furthermore, nationwide increased awareness of respiratory disease surges has resulted in most hospitals and urgent care facilities increasing their point-of-care testing capabilities. The development of cross-immunization programs and investments in decentralized diagnostics have facilitated the broad use of RIDTs across Europe in both developing and developed countries' healthcare settings.
   

Asia Pacific Rapid Influenza Diagnostic Tests Market
 

The Asia Pacific market was valued at USD 377 million in 2025.
 

• The RIDT industry in the Asia Pacific is expanding rapidly due to factors such as a large population, recurrent influenza epidemics, and increasing availability of primary care.
   
• Japan, South Korea, China, and Australia are experiencing a strong demand for rapid and accurate testing due to their robust screening culture and government-sponsored programs dedicated to monitoring disease outbreaks.
   
• In addition, the growing use of digital healthcare tools, improved laboratory infrastructure, and increased access to affordable rapid antigen tests are contributing to the widespread use of these products in hospitals and clinics.
   
• Further, the growing private healthcare system in the Asia Pacific is also helping drive the growth of point-of-care diagnostic testing. As respiratory diseases continue to pose significant challenges for global public health, there may be an increasing need for scalable and efficient influenza testing solutions.
   

Latin America Rapid Influenza Diagnostic Tests Market
 

The Latin American market is anticipated to exhibit remarkable growth during the analysis period.
 

• RIDT adoption is on the rise as healthcare systems in Latin America look to improve their ability to identify and respond early to (seasonal) influenza and other circulating types of respiratory illness.
   
• Rapid diagnostic tests used in all types of healthcare settings are helping to fast-track patient care, thereby easing the burden on laboratories due to the large number of processing volumes.
   
• Further, as antigen-based test products become more widely available, the ability for community-based clinics and regional healthcare networks to provide these types of testing increases, allowing greater uptake and access.
   
• Moreover, public health education and awareness campaigns are being implemented to encourage appropriate and timely diagnosis and therefore help both providers and patients have greater awareness regarding these illnesses.
   

Middle East and Africa Rapid Influenza Diagnostic Tests Market
 

The Middle East and Africa market is expected to experience substantial growth over the analysis timeframe.
 

• The RIDT market in MEA is growing steadily as countries strengthen influenza surveillance and expand access to rapid diagnostic tools.
   
• In the Middle East, rising healthcare modernization and investments in laboratory capacity enable greater adoption of both rapid antigen and molecular testing. Gulf countries particularly support rapid diagnostics through well‑funded public health initiatives.
   
• In addition, the need for fast, actionable influenza diagnosis in resource‑constrained and high‑burden settings continues to drive interest in scalable, easy‑to‑use RIDT solutions.
   

Rapid Influenza Diagnostic Tests Market Share
 

The rapid influenza diagnostic test market is characterized by a tiered competitive structure, with global leaders dominating a significant portion of the market and numerous mid‑tier and regional players contributing to innovation and capacity.
 

Major companies such as Abbott, BD, Quidel, Roche, and Thermo Fisher Scientific remain central due to their strong diagnostic portfolios, global distribution networks, and continual advancements in rapid and molecular testing technologies. These players offer widely adopted influenza testing platforms and maintain high visibility across clinical, point‑of‑care, and decentralized healthcare settings. Together, these players accounted for around 65% share of the global market in 2025.
 

Additionally, the introduction of innovative molecular diagnostic RIDTs has changed the marketplace, especially in developed countries with high healthcare spending. Companies, including Beijing Wantai Biological Pharmacy and Guangzhou Wondfo Biotech, are expanding their product offerings and increasing the availability of flu diagnostic tests in rural areas. This expansion is driving the growth of diagnostics in these regions. The competition in this region is leading to technological advancements and lower prices, making cost-effective RIDTs more accessible worldwide.
 

Moreover, the basic structure of the healthcare delivery system is shifting towards more decentralized models that support home sampling and other point-of-care diagnostic services. Companies worldwide are using new technologies, such as artificial intelligence-powered diagnostic devices and multiplex testing, to meet these needs. The combination of public health awareness and ongoing innovation is expected to drive the RIDT market in the coming years.
 

Rapid Influenza Diagnostic Tests Market Companies

A few of the prominent players operating in the global rapid influenza diagnostic tests industry include:

• 3B BlackBio
• Abbott
• Access Bio
• Becton, Dickinson and Company (BD)
• bioMérieux
• CHEMBIO
• DiaSorin
• Meridian
• Quidel Corporation
• Roche
• SEKISUI
• Siemens Healthineers
• Thermo Fisher Scientific

 

• Abbott

Focus on expanding rapid diagnostic portfolios, enhancing digital connectivity in point‑of‑care solutions, growing presence in decentralized care, and accelerating innovation through R&D, global partnerships, and scalable manufacturing capabilities.
 

• Becton, Dickinson and Company (BD)

Strengthening diagnostic platforms through automation and digital readout systems, invest in assay sensitivity improvements, expand global distribution, and pursue collaborations to enhance respiratory testing accuracy and clinical workflow integration.
 

• Roche

Advance molecular and rapid influenza testing through high‑performance platforms, integrate AI‑supported diagnostics, expand multi‑pathogen panels, and strengthen partnerships to scale access across hospitals, labs, and emerging markets worldwide.
 

Rapid Influenza Diagnostic Tests Industry News
 

• In October 2024, the FDA approved the Healgen Rapid Check COVID-19/Flu A&B Antigen Test for marketing. This at-home test, which uses a nasal swab, can detect both COVID-19 and influenza A & B. It’s available without a prescription and delivers results in just 15 minutes. This is the first over-the-counter flu test to receive marketing authorization outside emergency use. This approval expands at-home testing options, which is especially important as respiratory illnesses like flu and COVID-19 remain a concern.
   
• In May 2024, Watmind USA received FDA Emergency Use Authorization (EUA) for its SpeedySwab 15-Minute At-Home 3-in-1 Antigen Test. This test can identify COVID-19, influenza A, and influenza B. Developed in collaboration with NIH’s RADx ITAP, it provides a fast, easy-to-use, and affordable solution for individuals aged 2 and older to check their symptoms at home. Using lateral flow assay (LFA) technology, the test delivers quick results, helping users distinguish between these viruses, which often have overlapping symptoms.
   
• In March 2024, Co-Diagnostics, Inc.'s joint venture, CoSara, received approval from Indian regulators for its Influenza Multiplex PCR Test. This test can detect multiple influenza strains at the same time, making it a more efficient diagnostic tool for healthcare providers. This approval is a significant step toward improving access to advanced diagnostic testing in India.
   

The global rapid influenza diagnostic tests market research report includes an in-depth coverage of the industry with estimates and forecasts in terms of revenue in (USD Million) from 2022 - 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Conventional RIDTs
• Digital RIDTs

Market, By Technology

• Immunochromatographic assays
• Lateral flow assays
• Polymerase Chain Reaction
• Other technologies

Market, By Sample Type

• Nasal Swab
• Throat Swab
• Other samples

Market, By End Use

• Diagnostics centers
• Hospitals
• Research laboratories
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • UAE